AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26600564 — intervention group
Group type: COMPARATOR
Intervention: rDES (FKBI subgroup)
Number of subjects: 202
Study 24894026 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirst bundle (oral swab wipes, sterile ice-cold water sprays, lip moisturizer)
Number of subjects: 252
Study 24894026 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 252
Study 21388237 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 494
Study 21388237 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (tricyclic antidepressant)
Number of subjects: 494
Study 19333944 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 405
Study 19333944 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 405
Study 19333944 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 405
Study 17961421 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (target dose of 50 mg/d, actual achieved dose 36.25 +/- 14.31 mg/d in group 1 and 25.97 +/- 8.83 mg/d in group 2)
Number of subjects: 65
Study 17961421 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 65
Study 15368596 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 415
Study 11452745 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical wellbeing scale measuring headache, abdominal pain, and backache.
Number of subjects: 445
Study 11452745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental wellbeing scale measuring fatigue, stress, fear, depression, loneliness, helplessness, feeling of guilt, and low self‐complacency.
Number of subjects: 445
Study 11452745 — intervention group
Group type: EXPERIMENTAL
Intervention: Social wellbeing scale measuring perceived social support, relationship with mother, father, friends, and teacher.
Number of subjects: 445
Study 11452745 — intervention group
Group type: EXPERIMENTAL
Intervention: Total wellbeing scale.
Number of subjects: 445
Study 11452745 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-point Likert scale for assessing wellbeing indicators.
Number of subjects: 445
Study 9509226 — intervention group
Group type: EXPERIMENTAL
Intervention: Apply nitroglycerin ointment and stop i.v. nitroglycerin 30 minutes later
Number of subjects: 200
Study 9509226 — intervention group
Group type: COMPARATOR
Intervention: Decrease the dose of i.v. nitroglycerin by 10 micrograms/min every 15 minutes, apply one half the dose of nitroglycerin ointment when the original i.v. dose has been decreased by one half, and apply the full dose of the ointment when the i.v. nitroglycerin is stopped
Number of subjects: 200
Study 8092235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive management
Number of subjects: 95
Study 8092235 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 95
Study 3133689 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 49
Study 3133689 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 49
Study 3133689 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine
Number of subjects: 49
Study 31085860 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 90
Study 31085860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate (RL)
Number of subjects: 90
Study 31085860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Normal Saline and Ringer's Lactate (NS + RL)
Number of subjects: 90
Study 27878780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose treatment
Number of subjects: 30
Study 27878780 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study 26035756 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 100
Study 23756423 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser therapy
Number of subjects: 10
Study 23756423 — intervention group
Group type: COMPARATOR
Intervention: Mechanical preparation
Number of subjects: 10
Study 22384542 — intervention group
Group type: EXPERIMENTAL
Intervention: Erhuang Powder (EHP) applied externally once every 3 days for 2 courses (5 applications per course)
Number of subjects: 64
Study 22384542 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy of the cervix (Control group)
Number of subjects: 64
Study 19877980 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 16
Study 19877980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16428920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahaler (DPI) with doses of 130 and 360 microg/actuation
Number of subjects: 0
Study 16428920 — intervention group
Group type: COMPARATOR
Intervention: MDI (metered dose inhaler) with doses of 75 and 225 microg/actuation
Number of subjects: 0
Study 16428920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahaler (DPI) with new dose strengths of 100, 225, and 450 microg/actuation
Number of subjects: 0
Study 16428920 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro testing of DPI
Number of subjects: 0
Study 15173268 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish snus
Number of subjects: 105
Study 15173268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 105
Study 15173268 — intervention group
Group type: EXPERIMENTAL
Intervention: OMNI cigarettes
Number of subjects: 105
Study 11300572 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic future-event expectancies (Study 1)
Number of subjects: 0
Study 11300572 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary, manipulated expectancy standards (Studies 2-4)
Number of subjects: 0
Study 11300572 — intervention group
Group type: COMPARATOR
Intervention: Cognitive load condition
Number of subjects: 0
Study 11300572 — intervention group
Group type: COMPARATOR
Intervention: No cognitive load condition
Number of subjects: 0
Study 9646423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling of infertile couples
Number of subjects: 0
Study 9646423 — intervention group
Group type: COMPARATOR
Intervention: Ligation or embolization of the spermatic vein
Number of subjects: 0
Study 8181198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion of temazepam (0.4 mg/kg in 30 minutes)
Number of subjects: 9
Study 8181198 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion of temazepam (0.4 mg/kg in 120 minutes)
Number of subjects: 9
Study 8181198 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (vehicle infusion similar to fast infusion)
Number of subjects: 9
Study 3422553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 mL/kg)
Number of subjects: 60
Study 3422553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.1 mL/kg)
Number of subjects: 60
Study 31427344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Number of subjects: 492
Study 31427344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy plus movement sensor biofeedback
Number of subjects: 492
Study 31427344 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 492
Study 29652567 — intervention group
Group type: EXPERIMENTAL
Intervention: KAMUT khorasan products
Number of subjects: 40
Study 29652567 — intervention group
Group type: COMPARATOR
Intervention: Control wheat products
Number of subjects: 40
Study 26851890 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergy handbook (handbook group)
Number of subjects: 153
Study 26851890 — intervention group
Group type: COMPARATOR
Intervention: Control group (received handbook at conclusion of study)
Number of subjects: 153
Study 25011986 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) treatment
Number of subjects: 829
Study 25011986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated by orthopedic surgeons
Number of subjects: 829
Study 25011986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fractures prior to treatment initiation
Number of subjects: 829
Study 25011986 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 829
Study 22124575 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 237
Study 22124575 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 237
Study 22124575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 20626727 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (dosed up to 400 mg/d over 7 days, followed by 300 to 800 mg/d flexible dosing until study end)
Number of subjects: 362
Study 20626727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 20626727 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 362
Study 17355793 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein preservation
Number of subjects: 64
Study 17355793 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein ligation
Number of subjects: 64
Study 15774791 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (cisplatin, doxorubicin, high-dose methotrexate)
Number of subjects: 677
Study 15774791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy + muramyl tripeptide (MTP)
Number of subjects: 677
Study 15774791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy + ifosfamide
Number of subjects: 677
Study 15774791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy + ifosfamide + muramyl tripeptide (MTP)
Number of subjects: 677
Study 11940756 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ‐67657 1400 mg
Number of subjects: 21
Study 11940756 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ‐67657 700 mg
Number of subjects: 21
Study 11940756 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ‐67657 350 mg
Number of subjects: 21
Study 11940756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10072005 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 36
Study 10072005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36
Study 10072005 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 36
Study 7722020 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 16 weeks
Number of subjects: 89
Study 7722020 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg/day for 52 weeks
Number of subjects: 89
Study 2351367 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of perindopril tert‐butylamine salt by oral route (treatment A)
Number of subjects: 12
Study 2351367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous route (bolus in 5 min, treatment B)
Number of subjects: 12
Study 2351367 — intervention group
Group type: EXPERIMENTAL
Intervention: Equimolar dose of perindoprilat (6.1 mg) by intravenous route (infusion over 2 h, treatment C)
Number of subjects: 12
Study 7014042 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 14
Study 7014042 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 14
Study 7014042 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 14
Study 31867650 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg nicotine/g tobacco)
Number of subjects: 58
Study 31867650 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content cigarettes (15.8 mg/g)
Number of subjects: 58
Study 27894373 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 g/day for 24 weeks
Number of subjects: 58
Study 27894373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 26355134 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based guidelines for CKD
Number of subjects: 27
Study 25064019 — intervention group
Group type: EXPERIMENTAL
Intervention: $25 contingency management
Number of subjects: 26
Study 25064019 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 contingency management
Number of subjects: 26
Study 25064019 — intervention group
Group type: COMPARATOR
Intervention: $0 condition
Number of subjects: 26
Study 22291982 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intermittent Pringle maneuver (total-IPM)
Number of subjects: 24
Study 22291982 — intervention group
Group type: COMPARATOR
Intervention: Selective intermittent Pringle maneuver (sel-IPM)
Number of subjects: 24
Study 22291982 — intervention group
Group type: COMPARATOR
Intervention: No intermittent Pringle maneuver (no-IPM)
Number of subjects: 24
Study 19174118 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox-driven nebulization of salbutamol or epinephrine
Number of subjects: 96
Study 19174118 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-driven nebulization of salbutamol or epinephrine (control group)
Number of subjects: 96
Study 17460158 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 53
Study 17460158 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg BID
Number of subjects: 53
Study 17460158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 14693591 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 2-chloroprocaine with epinephrine
Number of subjects: 18
Study 14693591 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg 2-chloroprocaine with epinephrine
Number of subjects: 18
Study 14693591 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg 2-chloroprocaine with epinephrine
Number of subjects: 18
Study 14693591 — intervention group
Group type: COMPARATOR
Intervention: 30 mg 2-chloroprocaine without epinephrine
Number of subjects: 18
Study 14693591 — intervention group
Group type: COMPARATOR
Intervention: 45 mg 2-chloroprocaine without epinephrine
Number of subjects: 18
Study 14693591 — intervention group
Group type: COMPARATOR
Intervention: 60 mg 2-chloroprocaine without epinephrine
Number of subjects: 18
Study 12352146 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy
Number of subjects: 0
Study 9834568 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple drainage (3 patients)
Number of subjects: 9
Study 9834568 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsupialisation (3 patients)
Number of subjects: 9
Study 9834568 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitonnage (3 patients)
Number of subjects: 9
Study 8719015 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 35
Number of subjects: 58
Study 8719015 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 50
Number of subjects: 58
Study 1671603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipecacuanha-induced emesis
Number of subjects: 30
Study 1671603 — intervention group
Group type: COMPARATOR
Intervention: Gastric lavage
Number of subjects: 30
Study 350495 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg oxaprozin daily
Number of subjects: 40
Study 350495 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oxaprozin daily
Number of subjects: 40
Study 350495 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.9 g daily)
Number of subjects: 40
Study 350495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin
Number of subjects: 40
Study 350495 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 40
Study 31422655 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.25% bupivacaine
Number of subjects: 75
Study 31422655 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 1% lidocaine
Number of subjects: 75
Study 31422655 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.25% bupivacaine plus 5 mL of 1% lidocaine
Number of subjects: 75
Study 31422655 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 28537355 — intervention group
Group type: EXPERIMENTAL
Intervention: HARMONIC scalpel (Group 1)
Number of subjects: 100
Study 28537355 — intervention group
Group type: COMPARATOR
Intervention: Clamp, tie, and electrocautery (Group 2)
Number of subjects: 100
Study 28537355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 100
Study 24375837 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI treatment (14 days enteral omeprazole)
Number of subjects: 40
Study 24375837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23850416 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV vaccine (AS04-adjuvanted herpes simplex virus type 2 glycoprotein D subunit vaccine)
Number of subjects: 0
Study 23850416 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 0
Study 23850416 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Havrix™; HAV control)
Number of subjects: 0
Study 21459215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 345
Study 21459215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab combined with laser
Number of subjects: 345
Study 21459215 — intervention group
Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 345
Study 19824016 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g unground flaxseed
Number of subjects: 16
Study 19824016 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g sesame seed
Number of subjects: 16
Study 19824016 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 g unground flaxseed + 12.5 g sesame seed (flaxseed+sesame seed bar, FSB)
Number of subjects: 16
Study 19242131 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL/kg of fluid over 15 minutes followed by dopamine
Number of subjects: 147
Study 19242131 — intervention group
Group type: COMPARATOR
Intervention: 20 mL/kg over 20 minutes up to a maximum of 60 mL/kg over 1 hour followed by dopamine
Number of subjects: 147
Study 15198901 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS supplemented formula (0.24 g/dl)
Number of subjects: 0
Study 15198901 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 0
Study 15198901 — intervention group
Group type: COMPARATOR
Intervention: Negative control formula (without oligosaccharides)
Number of subjects: 0
Study 15198901 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS supplemented formula and human milk
Number of subjects: 0
Study 12374874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus alteplase
Number of subjects: 256
Study 12374874 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus placebo
Number of subjects: 256
Study 10732800 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat genotyping in schizophrenia patients
Number of subjects: 219
Study 10732800 — intervention group
Group type: COMPARATOR
Intervention: CAG repeat genotyping in bipolar I disorder patients
Number of subjects: 219
Study 8078650 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced zinc oxide eugenol (EBA) cement
Number of subjects: 0
Study 8078650 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 0
Study 2644950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol dynamics abnormalities (fasting hypercortisolemia and absent diurnal variation)
Number of subjects: 35
Study 2644950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response to dexamethasone suppression
Number of subjects: 35
Study 2644950 — intervention group
Group type: EXPERIMENTAL
Intervention: 0800 cortisol levels
Number of subjects: 35
Study 234668 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (30 mg per day)
Number of subjects: 22
Study 234668 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (120 mg per day)
Number of subjects: 22
Study 234668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11264555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (human recombinant B‐type natriuretic peptide)
Number of subjects: 1700
Study 30527477 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch Surgery (TS) application for simulation training
Number of subjects: 40
Study 30527477 — intervention group
Group type: COMPARATOR
Intervention: Written information (control)
Number of subjects: 40
Study 30527477 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance comparison
Number of subjects: 40
Study 29438607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention site (engagement of staff, education, electronic reminders)
Number of subjects: 0
Study 29438607 — intervention group
Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 0
Study 27025337 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical tuberculosis therapy
Number of subjects: 850
Study 27025337 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid preventive therapy
Number of subjects: 850
Study 24824310 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab + chlorambucil (GClb)
Number of subjects: 238
Study 24824310 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil alone (Clb)
Number of subjects: 238
Study 22697273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg/day)
Number of subjects: 24
Study 22697273 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day)
Number of subjects: 24
Study 22697273 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of Lobeglitazone and Metformin
Number of subjects: 24
Study 22697273 — intervention group
Group type: COMPARATOR
Intervention: Lobeglitazone alone
Number of subjects: 24
Study 22697273 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 24
Study 20181679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aspirin (25 mg BID) and extended-release dipyridamole (200 mg BID)
Number of subjects: 1360
Study 20181679 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 1360
Study 17361245 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 75
Study 17361245 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol GFS
Number of subjects: 75
Study 17361245 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost after switching from timolol GFS
Number of subjects: 75